Literature DB >> 16467949

[Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?].

B Manger1, E Menge, R Schaefer, C Haase, J Seidel, H Michels.   

Abstract

The lysosomal storage diseases Gaucher disease, Fabry disease and MPS I are rare inheritable metabolic disorders that are now treatable with enzyme replacement therapy. In order to avoid irreversible complications, an early diagnosis and initiation of therapy is important. Due to the musculoskeletal symptoms associated with these storage diseases, patients are likely to visit a rheumatologist, who should, therefore, be able to recognise and diagnose these rare diseases. On the basis of the causal factors behind Gaucher disease, Fabry disease und MPS I (here Scheie syndrome), key symptoms that the rheumatologist (internist or paediatrician) should be familiar with for the differential diagnosis of these patients will be discussed. In addition, a short introduction to the pathophysiology and data on the prognosis and therapy for these diseases will be presented.

Entities:  

Mesh:

Year:  2006        PMID: 16467949     DOI: 10.1007/s00393-006-0039-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  29 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

Authors:  R O BRADY; J N KANFER; D SHAPIRO
Journal:  Biochem Biophys Res Commun       Date:  1965-01-18       Impact factor: 3.575

3.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

4.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

Review 6.  [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000].

Authors:  C Niederau; A Rolfs; S vom Dahl; D Häussinger; L W Poll; E Mengel; M Beck
Journal:  Med Klin (Munich)       Date:  2001-01-15

7.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

8.  Gaucher's disease: a disease with chronic stimulation of the immune system.

Authors:  Y Shoenfeld; L A Gallant; M Shaklai; E Livni; M Djaldetti; J Pinkhas
Journal:  Arch Pathol Lab Med       Date:  1982-08       Impact factor: 5.534

9.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  The presenting features of mucopolysaccharidosis type IH (Hurler syndrome).

Authors:  M A Cleary; J E Wraith
Journal:  Acta Paediatr       Date:  1995-03       Impact factor: 2.299

View more
  1 in total

Review 1.  [Lysosomal storage diseases].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.